In vivo dopamine transporter imaging in a unilateral 6-hydroxydopamine rat model of parkinson disease using 11C-methylphenidate PET

Journal of Nuclear Medicine

Volumn 53, Issue 5, 2012, Pages 813-822

  Sossi, Vesna ^a   Dinelle, Katherine ^a   Jivan, Salma ^a,b   Fischer, Kristina ^c   Holden, James E ^d   Doudet, Doris ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b TRIUMF   (Canada)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

DAT imaging; Parkinson's model; PET; Rodent

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DESIPRAMINE; DOPAMINE TRANSPORTER; LIGAND; METHYLPHENIDATE C 11; OXIDOPAMINE; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DENSITY; DISEASE MODEL; DISEASE SEVERITY; DISSOCIATION CONSTANT; IN VIVO STUDY; MALE; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RECEPTOR DENSITY; RODENT; SCATCHARD PLOT;

ANIMALS; CARBON RADIOISOTOPES; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; METHYLPHENIDATE; OXIDOPAMINE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84860744194     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.101436     Document Type: Article

References (30)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5:525-535. (Pubitemid 44262284)
2. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG. Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter. J Neurochem. 1997;69:1322-1325. (Pubitemid 27364858)
3. Bannon MJ. The dopamine transporter: Role in neurotoxicity and human disease. Toxicol Appl Pharmacol. 2005;204:355-360. (Pubitemid 40545237)
4. Nandhagopal R, Mak E, Schulzer M, et al. Progression of dopaminergic dysfunction in a LRRK2 kindred: A multitracer PET study. Neurology. 2008;71: 1790-1795.
5. Sossi V, la Fuente-Fernández R, Nandhagopal R, et al. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord. 2010;25:2717-2723.
6. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol. 2000;47:493-503. (Pubitemid 30194606)
7. Sossi V, de la Fuente-Fernández R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ. Dopamine transporter relation to dopamine turnover in Parkinson's disease: A positron emission tomography study. Ann Neurol. 2007;62:468-474. (Pubitemid 350308771)
8. Troiano AR, de la Fuente-Fernandez R, Sossi V, et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology. 2009;72: 1211-1216.
9. Cilia R, Ko JH, Cho SS, et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol Dis. 2010;39:98-104.
10. Sossi V, Dinelle K, Schulzer M, Mak E, Doudet DJ, de la Fuente-Fernández R. Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release. Eur J Nucl Med Mol Imaging. 2010;37:2364-2370.
11. Parkinson's Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson's disease progression. JAMA. 2002;287:1653-1661.
12. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology. 2001;56:1559-1564. (Pubitemid 32544560)
13. Blandini F, Armentero MT, Martignoni E. The 6-hydroxydopamine model: News from the past. Parkinsonism Relat Disord. 2008;14(suppl 2):S124-S129.
14. Cenci MA, Ohlin KE. Rodent models of treatment-induced motor complications in Parkinson's disease. Parkinsonism Relat Disord. 2009;(suppl 4):S13-S17.
15. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007; 27:1533-1539. (Pubitemid 47301451)
16. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840. (Pubitemid 26292051)
17. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
18. Topping GJ, Dinelle K, Kornelsen R, McCormick S, Holden JE, Sossi V. Positron emission tomography kinetic modeling algorithms for small animal dopaminergic system imaging. Synapse. 2010;64:200-208.
19. Schiffer WK, Alexoff DL, Shea C, Logan J, Dewey SL. Development of a simultaneous PET/microdialysis method to identify the optimal dose of 11C-raclopride for small animal imaging. J Neurosci Methods. 2005;144:25-34. (Pubitemid 40546299)
20. Holden JE, Jivan S, Ruth TJ, Doudet DJ. In vivo receptor assay with multiple ligand concentrations: An equilibrium approach. J Cereb Blood Flow Metab. 2002;22:1132-1141. (Pubitemid 35006806)
21. Studenov AR, Jivan S, Lu J, et al. J Labelled Comp Radiopharm. 1994;49: 455-458.
22. Sossi V, Dinelle K, Topping G, et al. Dopamine transporter relation to levodopaderived synaptic dopamine in a rat model of Parkinsonism's: An in vivo imaging study. J Neurochem. 2009;109:85-92.
23. Breese GR, Traylor TD. Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br J Pharmacol. 1971;42:88-99.
24. Kim JS, Lee JS, Im KC, et al. Performance measurement of the microPET Focus 120 scanner. J Nucl Med. 2007;48:1527-1535.
25. Rubins DJ, Meadors AK, Yee S, Melega WP, Cherry SR. Evaluation of a stereotactic frame for repositioning of the rat brain in serial positron emission tomography imaging studies. J Neurosci Methods. 2001;107:63-70. (Pubitemid 32492298)
26. Sossi V, Holden JE, Topping GJ, et al. In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD. J Cereb Blood Flow Metab. 2007;27:1407-1415. (Pubitemid 46985355)
27. Doudet DJ, Holden JE. Sequential versus nonsequential measurement of density and affinity of dopamine D2 receptors with [11C]raclopride: Effect of methamphetamine. J Cereb Blood Flow Metab. 2003;23:1489-1494. (Pubitemid 38018268)
28. Fischer K, Sossi V, Schmid A, et al. Noninvasive nuclear imaging enables the in vivo quantification of striatal dopamine receptor expression and raclopride affinity in mice. J Nucl Med. 2011;52:1133-1141.
29. Rinne JO, Laihinen A, Ruottinen H, et al. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: A PET study with [11C]raclopride. J Neurol Sci. 1995;132:156-161.
30. Doudet DJ, Jivan S, Ruth TJ, Holden JE. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: A PET study with [11C]raclopride. Synapse. 2002;44:198-202.